Therapy resistance on the RADar in ovarian cancer

Ovarian cancer has the worst prognosis of all gynecological cancers with high‐grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwickert, Jonas, Zickgraf, Franziska M, Sprick, Martin R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103092/
https://www.ncbi.nlm.nih.gov/pubmed/33779077
http://dx.doi.org/10.15252/emmm.202114010
_version_ 1783689246577524736
author Schwickert, Jonas
Zickgraf, Franziska M
Sprick, Martin R
author_facet Schwickert, Jonas
Zickgraf, Franziska M
Sprick, Martin R
author_sort Schwickert, Jonas
collection PubMed
description Ovarian cancer has the worst prognosis of all gynecological cancers with high‐grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high‐grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021).
format Online
Article
Text
id pubmed-8103092
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81030922021-05-10 Therapy resistance on the RADar in ovarian cancer Schwickert, Jonas Zickgraf, Franziska M Sprick, Martin R EMBO Mol Med News & Views Ovarian cancer has the worst prognosis of all gynecological cancers with high‐grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high‐grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021). John Wiley and Sons Inc. 2021-03-29 2021-05-07 /pmc/articles/PMC8103092/ /pubmed/33779077 http://dx.doi.org/10.15252/emmm.202114010 Text en © 2021 The Authors. Published under the terms of the CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Schwickert, Jonas
Zickgraf, Franziska M
Sprick, Martin R
Therapy resistance on the RADar in ovarian cancer
title Therapy resistance on the RADar in ovarian cancer
title_full Therapy resistance on the RADar in ovarian cancer
title_fullStr Therapy resistance on the RADar in ovarian cancer
title_full_unstemmed Therapy resistance on the RADar in ovarian cancer
title_short Therapy resistance on the RADar in ovarian cancer
title_sort therapy resistance on the radar in ovarian cancer
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103092/
https://www.ncbi.nlm.nih.gov/pubmed/33779077
http://dx.doi.org/10.15252/emmm.202114010
work_keys_str_mv AT schwickertjonas therapyresistanceontheradarinovariancancer
AT zickgraffranziskam therapyresistanceontheradarinovariancancer
AT sprickmartinr therapyresistanceontheradarinovariancancer

Ejemplares similares